1. Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy
- Author
-
Mary Shannon, Brian K. Link, James E. Wooldridge, Vikram K. Chand, and Justine M. Ritchie
- Subjects
Male ,Cancer Research ,medicine.medical_specialty ,Neutropenia ,Time Factors ,Fever ,Dacarbazine ,medicine.medical_treatment ,Vinblastine ,Gastroenterology ,Disease-Free Survival ,Cohort Studies ,Bleomycin ,hemic and lymphatic diseases ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Chemotherapy ,business.industry ,Hematology ,Hodgkin's lymphoma ,medicine.disease ,Hodgkin Disease ,Surgery ,Treatment Outcome ,Oncology ,ABVD ,Doxorubicin ,Absolute neutrophil count ,Female ,business ,Febrile neutropenia ,medicine.drug - Abstract
When uncomplicated neutropenia during doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy for the treatment of Hodgkin's lymphoma is encountered, it is unclear whether or not treatment should be modified. In the present study, we determined the incidence of neutropenia, febrile neutropenia, and the relationship of febrile neutropenia to grade III/IV neutropenia and dose modification, in a large university patient population. We reviewed the charts of patients diagnosed with Hodgkin's lymphoma between 1 January 1990 and 31 December 2002 who were treated with ABVD chemotherapy, and seen at the University of Iowa with complete diagnosis, staging, and treatment dosing records. Adequate data was available on 894 treatments in 81 patients with Hodgkin's lymphoma treated with ABVD chemotherapy. Grade III/IV neutropenia was present on the scheduled day of treatment in 187 (20.9%) treatments in 64 (79%) patients. Grade III/IV neutropenia was most common at cycle 1 day 15. Febrile neutropenia developed nine times in eight patients, and eight episodes of febrile neutropenia developed when the treatment-day absolute neutrophil count (ANC) > or =1000. Dose delay of >4 days and/or dose reduction to
- Published
- 2006
- Full Text
- View/download PDF